final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol
49. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison
of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of
Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
J Clin Oncol 2005;23:4634–42.
50. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter
JN, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 2012;366:399–408.
51. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in
classic Hodgkin’s lymphoma. N Engl J Med 2010;362:875–85.
52. Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in
classical Hodgkin’s lymphoma. Haematologica 2011;96:269–76.
53. Agostinelli C, Gallamini A, Stracqualursi L, et al. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin’s lymphoma: a retrospective, European, multicentre cohort
study. Lancet Haematol 2016;3:e467–e79.
54. Meignan M, Gallamini A, Meignan M, et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymph 2009;50:
55. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-
2-deoxy-D-glucose positron emission tomography is prognostically superior
to international prognostic score in advanced-stage Hodgkin’s lymphoma: a
report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746–52.
56. Easson EC, Russell MH. Cure of Hodgkin’s Disease. Br Med J 1963;
57. Kaplan HS. The radical radiotherapy of regionally localized Hodgkin’s disease. Radiology 1962;78:553–61.
58. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for
clinical stage I or II Hodgkin’s lymphoma: long-term results of the European
Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128–35.
59. Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of
Hodgkin’s lymphoma. Eur J Haematol Suppl 2005:135–40.
60. Bloomfield CD PT, Glicksman AS, et al. Chemotherapy and combined
modality therapy for Hodgkin’s disease: A progress report on cancer and
leukemia group B studies. Cancer Treat Rep 1982;66:835–46.
61. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s
disease. J Natl Cancer Inst 1988;80:1466–73.
62. Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin’s
disease with bulky disease. Clin Lab Haematol 1998;20:95–9.
63. Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica 2010;95:494–500.
64. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field
radiation in early-stage Hodgkin’s disease. N Engl J Med 2007;357:1916–27.
65. Landgren O, Axdorph U, Fears TR, et al. A population-based cohort study
on early-stage Hodgkin lymphoma treated with radiotherapy alone: with
special reference to older patients. Ann Oncol 2006;17:1290– 5.
66. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640–52.
67. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Eng J Med 2015;372:1598–607.
68. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11
trial. J Clin Oncol 2010;28:4199–206.
69. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early
unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin
Study Group HD14 trial. J Clin Oncol 2012;30:907–13.
70. Advani RH, Hong F, Fisher RI, et al. Randomized phase III trial comparing
ABVD plus radiotherapy with the Stanford V regimen in patients with stages I
or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis
of the North American Intergroup E2496 Trial. J Clin Oncol 2015;33:1936–42.
71. Sasse S, Brockelmann PJ, Georgen H, et al. Long-term follow-up of con-
temporary treatment in early-stage Hodgkin lymphoma: Updated analyses
of the German Hodgkin Study Group HD7, HD8, HD10 and HD11 trials.
J Clin Oncol 2017 Apr 18:JCO2016709410. doi: 10.1200/JCO.2016.70.9410.
[Epub ahead of print]
72. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German
Hodgkin Study Group. J Clin Oncol 2008;26:434–9.
73. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy
alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective
multicenter study of the Australasian Radiation Oncology Lymphoma
Group. Cancer 2005;104:1221–9.
74. Chera BS, Olivier K, Morris CG, et al. Clinical presentation and outcomes of
lymphocyte-predominant Hodgkin disease at the University of Florida. Am J
Clin Oncol 2007;30:601–6.
75. Chen RC, Chin MS, Ng AK, et al. Early-stage, lymphocyte-predominant
Hodgkin’s lymphoma: patient outcomes from a large, single-institution
series with long follow-up. J Clin Oncol 2010;28:136–41.
76. Savage KJ, Skinnider B, Al-Mansour M, et al. Treating limited-stage nodular
lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin
lymphoma with ABVD may improve outcome. Blood 2011;118:4585–90.
77. Eichenauer DA FM, Pluetschow A, et al. Phase 2 study of rituximab in newly
diagnosed stage IA nodular lymphocytepredominant Hodgkin lymphoma:
a report from the German Hodgkin Study Group. Blood 2011;118:4363–5.
78. Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study
of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014;32:912–8.
79. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in
58 children with limited stage, lymphocyte-predominant Hodgkin lympho-ma-experience from the European network group on pediatric Hodgkin
lymphoma. Cancer 2007;110:179–85.
80. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011;154: 23–31.
81. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its
treatment. J Clin Oncol 2011;29:1885–92.
82. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term
cause-specific mortality of patients treated for Hodgkin’s disease. J Clin
83. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy
(INRT) in patients with early Hodgkin lymphoma: concepts and guidelines.
Radiother Oncol 2006;79:270– 7.
84. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a
component of combination therapy for limited-stage Hodgkin’s lymphoma:
a question of field size. J Clin Oncol 2008;26:5170– 4.
85. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission
tomography on prediction of freedom from progression after Stanford V
chemotherapy in Hodgkin’s disease. J Clin Oncol 2007;25:3902–7.
86. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four
cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s
lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma
Study Group. J Clin Oncol 2003;21:3601–8.
87. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630–7.
88. Pavone V, Ricardi U, Luminari S, et al. ABVD plus radiotherapy versus EVE plus
radiotherapy in unfavorable stage IA and IIA Hodgkin’s lymphoma: results from
an Intergruppo Italiano Linfomi randomized study. Ann Oncol 2008;19:763–8.
89. De Bruin ML, Sparidans J, van’t Veer MB, et al. Breast cancer risk in female
survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes.
J Clin Oncol 2009;27:4239–46.
90. Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011;2011:323–9.
91. Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular
disease after involved node radiotherapy versus mantle field for Hodgkin
lymphoma. Int J Radiat Oncol Biol Phys 2012;83:1232–7.
92. Campbell BA, Hornby C, Cunninghame J, et al. Minimising critical organ
irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the
benefit of involved node radiotherapy. Ann Oncol 2012;23:1259–66.
93. Pingali SR, Jewell SE, Havlat L, et al. Limited utility of routine surveillance
imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer 2014;120:2122–9.